![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the 
-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]
Departments of In Vivo Neuroscience (J.D.B., M.T.J., F.O., J.M., T.L.W., J.R.A.), Medicinal Chemistry (A.N., T.H.), Drug Metabolism and Pharmacokinetics (C.P., M.R.), and Molecular and Cellular Neuroscience (S.E., H.D.L., M.S.S.), The Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Harlow, Essex, United Kingdom
The efficacy of 
-secretase inhibitors in vivo has, to date, been generally assessed in transgenic mouse models expressing increased levels of amyloid-
(A) peptide thereby allowing the detection of changes in A production. However, it is not clear whether the in vivo potency of -secretase inhibitors is independent of the level of amyloid precursor protein expression. In other words, does a -secretase inhibitor have the same effect in nontransgenic physiological animals versus transgenic overexpressing animals? In the present study, an immunoassay has been developed which can detect A(40) in the rat brain, where concentrations are much lower than those seen in transgenic mice such as Tg2576 (c. 0.7 and 25 nM, respectively) and in cerebrospinal fluid (CSF, c. 0.3 nM). Using this immunoassay, the effects of the -secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide] were assessed and robust dose-dependent reductions in rat brain and CSF A(40) levels were observed with ID50 values of 1.3 mg/kg for both brain and CSF. These values were comparable with those calculated for LY-411575 in transgenic mice. Time course experiments using LY-411575 demonstrated comparable temporal reductions in rat brain and CSF A(40), further suggesting these two pools of A are related. Accordingly, when all the data for the dose-response curve and time course were correlated, a strong association was observed between the brain and CSF A(40) levels. These data demonstrate the utility of the rat as a novel approach for assessing the effects of -secretase inhibitors on central nervous system A(40) levels in vivo.
Address correspondence to: Jonathan Best, Department of In Vivo Neuroscience, The Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Harlow, Essex, CM20 2QR, UK. E-mail: jonathan_best{at}merck.com
This article has been cited by other articles:
|
|
 |
|
  I. Thompson, J. McGiven, J. Sawyer, R. Thirlwall, N. Commander, and J. Stack Competitive Electrochemiluminescence Wash and No-Wash Immunoassays for Detection of Serum Antibodies to Smooth Brucella Strains Clin. Vaccine Immunol., May 1, 2009; 16(5): 765 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sankaranarayanan, M. A. Holahan, D. Colussi, M.-C. Crouthamel, V. Devanarayan, J. Ellis, A. Espeseth, A. T. Gates, S. L. Graham, A. R. Gregro, et al. First Demonstration of Cerebrospinal Fluid and Plasma A{beta} Lowering with Oral Administration of a {beta}-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 131 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Han, M.-l. Zhou, F. Abousaleh, R. P. Brendza, H. H. Dietrich, J. Koenigsknecht-Talboo, J. R. Cirrito, E. Milner, D. M. Holtzman, and G. J. Zipfel Cerebrovascular Dysfunction in Amyloid Precursor Protein Transgenic Mice: Contribution of Soluble and Insoluble Amyloid-{beta} Peptide, Partial Restoration via {gamma}-Secretase Inhibition J. Neurosci., December 10, 2008; 28(50): 13542 - 13550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Abramowski, K.-H. Wiederhold, U. Furrer, A.-L. Jaton, A. Neuenschwander, M.-J. Runser, S. Danner, J. Reichwald, D. Ammaturo, D. Staab, et al. Dynamics of A{beta} Turnover and Deposition in Different {beta}-Amyloid Precursor Protein Transgenic Mouse Models Following {gamma}-Secretase Inhibition J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 411 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Meredith Jr., L. A. Thompson, J. H. Toyn, L. Marcin, D. M. Barten, J. Marcinkeviciene, L. Kopcho, Y. Kim, A. Lin, V. Guss, et al. P-Glycoprotein Efflux and Other Factors Limit Brain Amyloid {beta} Reduction by {beta}-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitors in Mice J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 502 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cacucci, M. Yi, T. J. Wills, P. Chapman, and J. O'Keefe Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model PNAS, June 3, 2008; 105(22): 7863 - 7868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Hebert, K. Horre, L. Nicolai, A. S. Papadopoulou, W. Mandemakers, A. N. Silahtaroglu, S. Kauppinen, A. Delacourte, and B. De Strooper Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/{beta}-secretase expression PNAS, April 29, 2008; 105(17): 6415 - 6420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sankaranarayanan, E. A. Price, G. Wu, M.-C. Crouthamel, X.-P. Shi, K. Tugusheva, K. X. Tyler, J. Kahana, J. Ellis, L. Jin, et al. In Vivo {beta}-Secretase 1 Inhibition Leads to Brain A{beta} Lowering and Increased {alpha}-Secretase Processing of Amyloid Precursor Protein without Effect on Neuregulin-1 J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 957 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Szekeres, K. Leong, T. A. Day, A. E. Kingston, and E. H. Karran Development of Homogeneous 384-Well High-Throughput Screening Assays for A{beta}1-40 and A{beta}1-42 Using AlphaScreenTM Technology J Biomol Screen, February 1, 2008; 13(2): 101 - 111. [Abstract] [PDF]
|
|
|
|
|
|
M. E. Goldstein, Y. Cao, T. Fiedler, J. Toyn, L. Iben, D. M. Barten, M. Pierdomenico, J. Corsa, C. V. C. Prasad, R. E. Olson, et al. Ex Vivo Occupancy of {gamma}-Secretase Inhibitors Correlates with Brain beta-Amyloid Peptide Reduction in Tg2576 Mice J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Best, D. W. Smith, M. A. Reilly, R. O'Donnell, H. D. Lewis, S. Ellis, N. Wilkie, T. W. Rosahl, P. A. Laroque, C. Boussiquet-Leroux, et al. The Novel {gamma} Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 552 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Hyde, N. A. McHugh, J. Chen, Q. Zhang, D. Manfra, A. A. Nomeir, H. Josien, T. Bara, J. W. Clader, L. Zhang, et al. Studies to Investigate the in Vivo Therapeutic Window of the {gamma}-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 Mouse J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1133 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Aisen, D. Saumier, R. Briand, J. Laurin, F. Gervais, P. Tremblay, and D. Garceau A Phase II study targeting amyloid-{beta} with 3APS in mild-to-moderate Alzheimer disease Neurology, November 28, 2006; 67(10): 1757 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Chen, E. A. Eckman, and C. B. Eckman Reductions in levels of the Alzheimer's amyloid {beta} peptide after oral administration of ginsenosides FASEB J, June 1, 2006; 20(8): 1269 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Best, M. T. Jay, F. Otu, I. Churcher, M. Reilly, P. Morentin-Gutierrez, C. Pattison, T. Harrison, M. S. Shearman, and J. R. Atack In Vivo Characterization of Abeta(40) Changes in Brain and Cerebrospinal Fluid Using the Novel {gamma}-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the Rat J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 786 - 790. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
